Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting
Why the study?
High lipoprotein(a) levels are associated with increased ASCVD risk, but the prevalence and characteristics of patients eligible for lipoprotein(a)-lowering therapies in real-world settings needed estimation.
Population
5961 Italian outpatients with dyslipidemia
Design
Pooled cohort study
Authors
Discussion
Loading...
Member takes
Implication
May identify real-world ASCVD patients eligible for Lp(a) therapies; leaves open outcome confirmation in trials.
Structured PICO
P
Population
5,961 Italian outpatients with dyslipidemia (men: 2879, women: 3982)
O
Outcome
Prevalence and characteristics of patients potentially eligible for Lp(a)-lowering therapies (patients with ASCVD and Lp(a) levels > 70 mg/dL)
In a large Italian cohort of outpatients with dyslipidemia, nearly 45% of those with ASCVD have Lp(a) > 70 mg/dL, indicating a substantial population potentially eligible for emerging Lp(a)-lowering therapies.
Cite This Study
Cicero et al. (2023) studied this question.